NCT07081334 2025-07-23
HPV
POSVAX
Phase 1 Completed
Clinical Trials
18 trialsNCT06454175 2025-01-06
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Active not recruiting
NCT00667563 2024-03-19
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
AIDS Malignancy Consortium
Phase 1 Completed
NCT03912831 2023-12-26
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
Phase 1 Terminated
NCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05672966 2023-01-06
Phase I Clinical Trial of a Candidate HPV Vaccine
Wuhan BravoVax Co., Ltd.
Phase 1 Unknown
NCT04083196 2021-11-24
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
National Vaccine and Serum Institute, China
Phase 1 Completed
NCT03929172 2020-07-01
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
2A Pharma AB
Phase 1 Completed
NCT03677960 2019-07-24
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Terminated
NCT03202992 2019-02-07
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Completed
NCT03085381 2018-09-14
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT00549900 2018-07-20
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
GlaxoSmithKline
Phase 1 Completed
NCT00685412 2017-09-13
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
Inovio Pharmaceuticals
Phase 1 Completed
NCT00478621 2017-05-10
Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)
GlaxoSmithKline
Phase 1 Completed
NCT00635830 2015-10-09
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00811408 2010-01-28
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Unknown